Please use this identifier to cite or link to this item:
|Title:||Role of the adaptive immune system in diabetic kidney disease.||Austin Authors:||Kong, Lingyun;Andrikopoulos, Sofianos;MacIsaac, Richard J;Mackay, Laura K;Nikolic-Paterson, David J;Torkamani, Niloufar ;Zafari, Neda;Marin, Evelyn C S;Ekinci, Elif I||Affiliation:||Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia..
College of Sport and Exercise Science, Victoria University, Melbourne, Victoria, Australia..
Endocrine Center of Excellence, Austin Health, Melbourne, Victoria, Australia..
Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia..
Department of Nephrology, Monash Medical Center and Monash University Center for Inflammatory Diseases, Melbourne, Victoria, Australia..
Medicine (University of Melbourne)
|Issue Date:||Feb-2022||metadata.dc.date:||2021||Publication information:||Journal of diabetes investigation 2022; 13(2): 213-226||Abstract:||Diabetic kidney disease (DKD) is a highly prevalent complication of diabetes and the leading cause of end-stage kidney disease. Inflammation is recognized as an important driver of progression of DKD. Activation of the immune response promotes a pro-inflammatory milieu and subsequently renal fibrosis, and a progressive loss of renal function. Although the role of the innate immune system in diabetic renal disease has been well characterized, the potential contribution of the adaptive immune system remains poorly defined. Emerging evidence in experimental models of DKD indicates an increase in the number of T cells in the circulation and in the kidney cortex, that in turn triggers secretion of inflammatory mediators such as interferon-γ and tumor necrosis factor-α, and activation of cells in innate immune response. In human studies, the number of T cells residing in the interstitial region of the kidney correlates with the degree of albuminuria in people with type 2 diabetes. Here, we review the role of the adaptive immune system, and associated cytokines, in the development of DKD. Furthermore, the potential therapeutic benefits of targeting the adaptive immune system as a means of preventing the progression of DKD are discussed.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/28877||DOI:||10.1111/jdi.13725||ORCID:||https://orcid.org/0000-0001-8058-6977
|Journal:||Journal of diabetes investigation||PubMed URL:||34845863||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/34845863/||Type:||Journal Article||Subjects:||Adaptive immune system
Diabetic kidney disease
|Appears in Collections:||Journal articles|
Show full item record
checked on May 26, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.